BDSI BioDelivery Sciences International Inc.

Biotech Analyst Ratings

Latest News

1. 27 April 2022 Genenta Announces Nomination of Mark A. Sirgo as Chair

   35 years industry experience including as CEO and founder of public company
   

   Stephen Squinto steps down as Chair for new role

   MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to pursue a new business opportunity.

   Dr. Sirgo most recently was CEO of Aruna Bio, Inc., a preclinical biotech company developing neural stem cells for the treatment of…

   View Full Article
2. 22 March 2022 Collegium Completes the Acquisition of BDSI

   STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI").
   

   "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integration and delivering identified synergies of at least $75…

   View Full Article
3. 24 February 2022 BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine

   The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults
   

   Expands BDSI Portfolio and Establishes Growth Platform in Neurology

   RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYB^TM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.

   "ELYXYB represents a significant innovation in the rapidly growing migraine market and our initial…

   View Full Article
4. 14 February 2022 BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences International to Collegium Pharmaceutical

   MONSEY, N.Y., Feb. 14, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) ("BDSI") acted in the best interests of BDSI shareholders in approving the sale of BDSI to Collegium Pharmaceutical ("Collegium") for $5.60 per share in cash.
   

   If you remain a BDSI shareholder and have questions about your legal rights, you may contact our firm at the following link to discuss your options at no charge:

   https://wohlfruchter.com/cases/biodelivery-sciences-international/

   Alternatively, you may contact us by phone at 866-833-6245, or via email at [email protected].

   Why is there an investigation?
   On February 14, 2022, BDSI announced an agreement…

   View Full Article
5. 14 February 2022 Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

   Transaction is valued at $5.60 per share representing a total equity value of $604 million

   Represents a 54% premium to BDSI stock's closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $3.40

   Transaction expected to close late in the first quarter of 2022

   RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it has entered into a definitive merger agreement for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to purchase all outstanding shares of BDSI at $5.60 per share in an all-cash transaction…

   View Full Article